|
1.
|
|
10 p, 768.8 KB |
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis : the prospective MABOMET GEICAM study
/
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Muñoz, M. (Hospital Clínic i Provincial de Barcelona) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Chacón, J.I. (Hospital Virgen de la Salud (Toledo)) ;
Cassinello, J. (Hospital General de Guadalajara) ;
Antolin, S. (Complejo Hospitalario U. A Coruña) ;
Adrover, Encarna (Complejo Hospitalario Universitario de Albacete) ;
Ramos, M. (Centro Oncológico de Galicia) ;
Carrasco, E. (GEICAM (Spanish Breast Cancer Group)) ;
Jimeno, M.A. (GEICAM (Spanish Breast Cancer Group)) ;
Ojeda, Belén (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
González, X. (Hospital General de Catalunya) ;
González, S. (Hospital Mutua de Terrassa. Barcelona) ;
Constenla, M. (Complejo Hospitalario De Pontevedra) ;
Florián, J. (Hospital Comarcal de Barbastro) ;
Miguel, A. (Hospital Althaia Manresa) ;
Llombart, A. (Hospital Arnau de Vilanova (València)) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Colomer, R. (Hospital Universitario de la Princesa (Madrid)) ;
Del Barco, S. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Universitat Autònoma de Barcelona
Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. [...]
2019 -  10.1186/s41687-019-0161-y
Journal of Patient-Reported Outcomes, Vol. 3 Núm. 1 (january 2019) , p. 72
|
|
|
2.
|
|
9 p, 1.1 MB |
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
/
Pons, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández-León, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Altaleb, Ahmad (Mubarak Al-Kabeer Hospital, Jabriya, Kuwait) ;
Ussene, Esperança (Hospital Vila Franca de Xira, Portugal) ;
Iglesias, Roman (Hospital Santa Barbara, Ciudad Real) ;
Castillo, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodríguez-Martínez, Paula (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Digital counting methods were developed to decrease the high intra- and inter-observer variability of immunohistochemical markers such as Ki67, with most presenting a good correlation coefficient (CC). [...]
2022 - 10.1038/s41598-022-11411-5
Scientific reports, Vol. 12 (may 2022)
|
|
|
3.
|
|
10 p, 3.7 MB |
SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
/
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Bernat-Peguera, Adrià (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ezeonwumelu, I.J (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teruel, Iris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clotet Sala, Bonaventura (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and certain solid tumours, although with controversial data. [...]
2023 - 10.3389/fimmu.2023.1112761
Frontiers in immunology, Vol. 14 (february 2023)
|
|
|
4.
|
|
16 p, 2.7 MB |
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
/
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez-Sáez, Olga (Universitat de Barcelona) ;
Sanfeliu, Esther (Hospital Clínic i Provincial de Barcelona) ;
Bellet Ezquerra, Meritxell (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pascual, Tomás (University of North Carolina) ;
Marín-Aguilera, Mercedes (Reveal Genomics (Barcelona)) ;
Rodríguez, Anna (Hospital Clínic i Provincial de Barcelona) ;
Chic, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Adamo, Barbara (Universitat de Barcelona) ;
Paré Brunet, Laia (Reveal Genomics (Barcelona)) ;
Vidal Losada, Maria (Universitat de Barcelona) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez-Rey, Marina (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Sánchez-Bayona, Rodrigo (Hospital Universitario 12 de Octubre (Madrid)) ;
Suñol, Anna (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ;
Tolosa, Pablo (Hospital Universitario 12 de Octubre (Madrid)) ;
Muñoz, Montserrat (SOLTI cooperative group (Barcelona)) ;
González-Farré, Blanca (Hospital Clínic i Provincial de Barcelona) ;
Villagrasa, Patricia (Reveal Genomics (Barcelona)) ;
Parker, Joel S. (University of North Carolina) ;
Perou, Charles M. (University of North Carolina) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0. [...]
2023 - 10.1038/s41467-023-36801-9
Nature communications, Vol. 14 (march 2023)
|
|
|
5.
|
|
23 p, 904.8 KB |
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
/
Ferrando-díez, Angelica (Institut Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol) ;
Felip, Enriqueta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pous, Anna (Institut Germans Trias i Pujol) ;
Sirven, Milana Bergamino (Institut Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T- DM1) and the reversible HER2 inhibitor lapatinib. [...]
2022 - 10.3390/cancers14143305
Cancers, Vol. 14 Núm. 14 (7-2 2022) , p. 3305
|
|
|
6.
|
|
20 p, 1.9 MB |
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types
/
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gómez, Maica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Romeo, Margarita (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Morán, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Layos, Laura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pérez-Roca, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. [...]
2022 - 10.20944/preprints202201.0141.v1
Cancers, Vol. 14 Núm. 3 (january 2022)
|
|
|
7.
|
|
2 p, 201.0 KB |
Erratum : Castellví, M. et al. Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers 2020, 12, 713
/
Castellví, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ezeonwumelu, I.J (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Badia, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pujantell, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Teruel, Iris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Este, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Universitat Autònoma de Barcelona
2020 - 10.3390/cancers12071728
Cancers, Vol. 12 (june 2020)
|
|
|
8.
|
|
|
9.
|
|
19 p, 2.6 MB |
Pharmacological modulation of SAMHD1 activity by CDK4/6 inhibitors improves anticancer therapy
/
Castellví, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ezeonwumelu, I.J (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Badia, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pujantell, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Teruel, Iris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Universitat Autònoma de Barcelona
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to viral restriction, cancer development and autoimmune disorders. [...]
2020 - 10.3390/cancers12030713
Cancers, Vol. 12 Núm. 3 (march 2020) , p. 713
|
|
|
10.
|
|
18 p, 288.5 KB |
Translational research opportunities regarding homologous recombination in ovarian cancer
/
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pardo, Juan Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Román, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). [...]
2018 - 10.3390/ijms19103249
International journal of molecular sciences, Vol. 19 Núm. 10 (19 2018) , p. 3249
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
